Recovery article

HGH Fragment 176-191 and Tesamorelin Interaction: Monitor | Peptide Database

Compound Profiles HGH Fragment 176-191 Growth Hormone Fragment | Fat Loss Peptide Mimics the lipolytic region of human growth hormone by stimulating fat breakdown through beta-3 adrenergic receptor pathways. Unlike full HGH, it does not bind the growth hormone

By Recovery & Performance Peptides Editorial Team Published September 9, 2026

Compound Profiles

HGH Fragment 176-191

Growth Hormone Fragment | Fat Loss Peptide

Mimics the lipolytic region of human growth hormone by stimulating fat breakdown through beta-3 adrenergic receptor pathways. Unlike full HGH, it does not bind the growth hormone receptor, so it does not increase IGF-1 levels or interfere with glucose metabolism.

Tesamorelin

GHRH Analog | Visceral Fat Reduction

Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat..

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take HGH Fragment 176-191 with Tesamorelin?

Yes, but with caution. Both HGH Fragment 176-191 and Tesamorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Regular monitoring is advised.

Is HGH Fragment 176-191 and Tesamorelin safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, insulin disrupting, teratogenic. Monitor accordingly.

What are the interactions between HGH Fragment 176-191 and Tesamorelin?

Both HGH Fragment 176-191 and Tesamorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.

How should I time HGH Fragment 176-191 and Tesamorelin?

HGH Fragment 176-191 has a half-life of 15-20 minutes and Tesamorelin has a half-life of 26-38 minutes. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

COACH'S BOARD / KEY POINTS

HGH Fragment 176-191 and AOD-9604 are the same molecular structure. A 15-amino-acid sequence (positions 176–191) derived from the C-terminus of human growth hormone, with identical 1817 Da molecular weight and amino acid composition.
The AOD-9604 designation originated from clinical trials conducted by Metabolic Pharmaceuticals between 2004 and 2007, while Fragment 176-191 remains the standard biochemical nomenclature used in research supplier catalogs and academic publications.
Both compounds failed to achieve FDA approval for obesity treatment after Phase IIb trials showed insufficient weight loss efficacy (2.6% vs 1.8% placebo) despite acceptable safety profiles and no IGF-1 elevation.
The peptide retains lipolytic activity by activating beta-3 adrenergic receptors on adipocytes without binding to growth hormone receptors. Making it valuable for metabolic research isolating fat mobilization from anabolic growth signaling.
Lyophilized Fragment 176-191 maintains >95% purity for 21 days post-reconstitution when stored at 2–8°C in amber vials, but oxidation at cysteine residues accelerates degradation beyond 28 days or after freeze-thaw cycles.
Research labs should specify Fragment 176-191 or AOD-9604 based on protocol citation requirements rather than assuming functional differences. The molecular identity is identical across suppliers meeting GMP synthesis standards.

SOURCE / realpeptides.co ↗

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

HGH Fragment 176-191 Dosage Calculator

Get your personalized HGH Fragment 176-191 dosage for fat loss based on your body weight, experience level, and goals.

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

HGH Fragment 176-191 5mg - High-Quality Research Peptide

HGH Fragment 176-191, offered at 5mg, is a high-quality specialised research peptide developed for advanced scientific exploration in metabolism and endocrinology. This product is ideal for laboratory settings where precision and reliability are paramount. Product Name: HGH Fragment 176-191 5mg Catalogue Number: HGHF176191-5mg Molecular Formula: C78H125N23O23S2 Molecular Weight: 1817.1 g/mol Purity: ≥98% Form: Lyophilised Solid

RESEARCH

Community Research

Join others researching HGH Fragment 176-191 — share findings, ask questions, and learn from real experiences HGH Fragment 176-191 is the fat-burning segment of human growth hormone, corresponding to amino acids 176 through 191 of the full GH molecule. It stimulates lipolysis and inhibits lipogenesis without the growth-promoting or insulin-disrupting effects associated with full-length HGH. AOD-9604 is a modified version of this fragment with an added N-terminal tyrosine residue. Mimics the lipolytic region of human growth hormone by stimulating fat breakdown through beta-3 adrenergic receptor pathways. Unlike full HGH, it does not bind the growth hormone receptor, so it does not increase IGF-1 levels or interfere with glucose metabolism. The fragment selectively targets adipose tissue to promote fat oxidation.

Product & matchup locker

Linked catalog and comparison files.

Comparison

HGH Fragment 176-191 vs Full-Length Growth Hormone

HGH Fragment 176-191 vs Full-Length Growth Hormone Discover how HGH Fragment 176-191 compares to full-length HGH 191AA in fat metabolism, IGF-1 activity, and systemic effects. Cho…

View details →